Novo Nordisk on Tuesday reported that its new weight problems tablet that objectives the amylin hormone resulted in really extensive weight reduction in an early learn about, boosting the corporate’s pipeline of next-generation applicants that can be more practical than Wegovy.
In a Segment 1 trial, a 50-mg dose of the day by day tablet known as amycretin, which turns on receptors of each the amylin and GLP-1 hormones, led to ten.4% weight reduction at about 3 months after the beginning of remedy. Individuals who took two tablets an afternoon had 13.1% weight reduction. In the meantime, the ones on placebo skilled 1.1% weight reduction, in step with an summary of knowledge that shall be introduced Wednesday at the yearly assembly of the Eu Affiliation for the Learn about of Diabetes.
The findings underline the opportunity of better and extra speedy weight reduction than what’s been observed with present medication in the marketplace. For comparability, Novo’s blockbuster Wegovy led to fifteen% weight reduction in its pivotal Segment 3 trial lasting over a 12 months.
STAT+ Unique Tale
Have already got an account? Log in
This text is unique to STAT+ subscribers
Release this text — plus day by day protection and research of the biotech sector — through subscribing to STAT+.
Have already got an account? Log in
Have already got an account? Log in
Particular person plans
Staff plans
View All Plans
Get limitless get entry to to award-winning journalism and unique occasions.
Subscribe
